A systematic review and meta-analysis of 50 randomized controlled trials did not find that vitamin and antioxidant supplements reduce the risk of cardiovascular disease. Numerous subgroup analyses similarly found no benefit from daily supplementation, but also no adverse effects.
The FDA has approved a buccal formulation of Acyclovir for the treatment of recurrent cold scores. The product uses a mucoadhesive technology that delivers the drug in high concentration to the site of the cold sore. Acyclovir buccal tablets are manufactured by Farmea in France and marketed as Sitavig by BioAlliance Pharma.